After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest ...

Donanemab In May of 2023, two months prior to the full approval of lecanemab, another promising treatment for the disease, Eli Lilly’s donanemab, emerged from Phase III trials.

A once-a-day pill that could completely revolutionise the treatment of Alzheimer’s disease has reached a significant ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's ...

Holstege was supported by ABOARD, a public-private partnership receiving funding from ZonMw and Health Holland, Topsector Life Sciences and Health, the Hans und Ilse Breuer Stiftung, the Horstingstuit ...

INmune Bio’s stock plunged by more than 50% after its TNF inhibitor failed to demonstrate efficacy in Alzheimer’s patients ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

Genes and Genetics News. Read today's medical research in genetics including what can damage genes, what can protect them, and more.

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease PR Newswire May 21, 2025, 1:21:00 PM ...

Learn about early diabetes symptoms, diabetic diet information, diabetes care, type 1 diabetes, insulin resistance and type 2 diabetes. Read the latest medical research on diabetes.